LabCorp and the Mount Sinai Health System announced another element in their shared goal of improving laboratory services and patient care. LabCorp, a leading global life sciences company, and Mount Sinai, New York City’s largest integrated healthcare delivery system, will work together to establish the Mount Sinai Digital and Artificial Intelligence (AI)-Enabled Pathology Center of Excellence.

“LabCorp and Mount Sinai continue to focus on innovations to enhance the quality and lower the costs of patient care, and we’re pleased to introduce digital pathology to Mount Sinai as the next phase of our collaboration,” said William B. Haas, senior vice president of LabCorp Diagnostics’ Northeast Division. “We’ve taken significant steps to enhance laboratory services across the Mount Sinai system since early 2017, and we look forward to continuing to build on those successes to advance LabCorp’s mission and our shared goal to improve health and improve lives.”

LabCorp, which has implemented the Philips IntelliSite Pathology Solution in four of its laboratories and plans to introduce it to additional laboratories, will use its experience and expertise to lead the integration of digital pathology into clinical practice across Mount Sinai’s hospitals. Initially, digital pathology will be used for interpretations of genitourinary malignancies, mainly prostate tumors, as well as cancers of the head and neck. The next planned stage of implementation is for Mount Sinai pathologists to use the digital pathology solution to provide consultations for cases interpreted by LabCorp’s Dianon Pathology specialty laboratory. This will give physicians and patients from across the U.S. access to the leading expertise of Mount Sinai specialists

The Center of Excellence will be housed within Mount Sinai’s Department of Pathology, Molecular and Cell-Based Medicine and will use the Philips IntelliSite Pathology Solution to expand digital pathology capabilities for primary diagnosis and consultations across the Mount Sinai system. The department processes more than 80 million diagnostic tests a year, making it one of the largest academic departments of its kind in the country.

“Digital pathology gives us the unprecedented opportunity to expand our services to the community at large, and engage members of our department, considered key opinion leaders in their field, to provide expert diagnostic opinions in complex cases. This, in addition to our new predictive AI-based tests, introduces the potential for optimization of treatment efficacy, and provides the opportunity for improved clinical outcomes,” said Carlos Cordon-Cardo, M.D., Ph.D., chairman of the Department of Pathology, Molecular and Cell-Based Medicine at Mount Sinai Health System and professor of Pathology, Genetics and Genomic Sciences, and Oncological Sciences at the Icahn School of Medicine at Mount Sinai.

Don Scanlon, chief financial officer and chief of corporate services at Mount Sinai, added, “The Digital and AI-Enabled Pathology Center of Excellence stands to offer major operational efficiencies, extending our joint unique resources and intellectual assets more effectively to improve the lives of patients.”

The Center of Excellence will include deployment of the Philips IntelliSite Pathology Solution at each of Mount Sinai’s eight hospitals and select ambulatory care locations. Digital pathology will allow for real-time pathology interpretations for physicians and patients throughout the New York metropolitan area without requiring the pathologist to be on-site where the patient is receiving care. Mount Sinai participated in Philips’ digital pathology performance evaluation to obtain market clearance in the U.S., gaining valuable expertise with the research version of the digital pathology system, providing the foundation for Mount Sinai’s AI diagnostic test development. Implementation of the clinical Philips IntelliSite Pathology Solution is underway and Mount Sinai expects to begin its use in the next several months.

“Digital pathology provides a unique opportunity to innovate laboratory pathology services and support pathologists in their daily practice,” said Marlon Thompson, general manager, Philips Digital & Computational Pathology. “The Philips IntelliSite Pathology Solution is designed for scale and clinical pathologists’ workflows, enabling immediate access to consultations and helping leading institutions such as Mount Sinai and LabCorp to collaborate and deliver high-quality care.”

The Philips IntelliSite Pathology Solution is the first, and currently the only, digital pathology solution marketed for primary diagnostic use in the U.S. It aids pathologists in the review and interpretation of digital images of surgical pathology slides through an automated digital pathology image creation, viewing and management system. With an ultra-fast scanner, image management system, high-resolution display and advanced software tools, the system aims to support more efficient workflows, faster turnaround times, and enhanced collaboration between pathologists to enhance diagnostic decision-making. LabCorp plans to expand digital pathology to more of its laboratories in the coming year and is working with key partners such as Mount Sinai to help support their transition to digital pathology and AI in the future.

The only satellite exhibition of MEDICA in China, Medical Fair China 2019 is co-organized by Messe Dusseldorf (Shanghai) Co., Ltd. and China Service Alliance of Medical Devices Innovation.

Together with Global Device Week, Medical Fair China is expected to attract over 15,000 medical top experts. As one of the grandest events in china medical industry, don’t miss it!

Introduction of Global Device Week
Global Device Week was first launched in 2018 by the China Service Alliance of Medical Devices Innovation and its partners. It aims to gather the world’s innovative talents, projects, products and resources at one location, to promote international innovation and cooperation, to speed up the achievements of medical apparatus and instruments research, to create a new environment for medical device innovation, and to creatively develop the medical device industry of China.

The first Global Device Week received strong support from the local government. 314 investment institutions and 283 speakers gathered at this event, which received an overwhelming response and good feedback from the industry.

In line with the market demand and strong appeal from enterprises, Global Device Week 2019 will continue the theme of the previous year, and the China Medical Devices Design and Startups Competition 2019 (CMDDSC) will be held with support from the Ministry of Science and Technology and the China National Center for Biotechnology Development, supported by three key forums – DeviceChina2019: China Medical Device Summit Forum, China Medical Innovation Forum 2019 (CMIF) and China Medical Device Transformation Medicine and Innovation Service Forum 2019 (TMIS) , and nearly 20 sub-sessions on professional topics will be held concurrently. The event will be a display of sheer brilliance.

The Competition: CMDDSC 2019
CMDDSC2019 will be divided into four categories: optical electro-mechanical, in vitro diagnostics, medical materials and accessories and artificial intelligence; and each of the 4 categories will have its own award category. In the preliminary & semifinal stage, the top 15 projects in each category (60 in total) will be selected based on their total score. The finals will be held in same hall of medical fair china. There will be 3 first prizes, 5 second prizes, and 7 third prizes of each category.

In 2018, over 500 top medical experts are gathering in the Competition, and all projects financing exceeded 1.7 billion yuan, which becoming a huge driving force in china medical industry. Now the organizer is dedicated to developing more quality projects on site.

Main Session 1: CMIF 2019
CMIF 2019 will be the 4th session, jointly hosted by China Strategic Alliance of Medical Device Innovation (CSAMDI) and Messe Düsseldorf (Shanghai) Co., Ltd. in a bid to promote innovation in China’s medical device industry from an international perspective, and to explore new ideas in exhibition services and transformation medicine and new cooperation among medical institutions and physician groups in the broad environment of innovation and development.

2019 topics will include the changes and interpretation of Chinese policies on medical device innovation, development trend of China’s medical device innovation and market, application of 3D additive manufacturing technology in innovative medical device R&D and production, application of big data and artificial intelligence (AI) in disease diagnosis, crossover assembly of AI + Medicare masters, all not to be missed.

Main Session 2?TMIS2019
TMIS aims to intensely analyze transformation of hospitals, research institutions and R&D departments of Chinese enterprises, combining production, teaching and research. Topics will cover significance of transformation promotion through innovation service providers, to make the innovation service sector a booster to the ecosystem for production, teaching, research, application and funding, and further push forward the process of China’s medical device innovation. Over 1,000 guests are expected to attend the Forum.

Main Session 3:Device China2019
Device China has been successfully held for eight years since 2011 as the premier event in China focusing on medical device industry development. Device China vigorously creates industry health ecosystem, discusses front development trends, builds special communication platforms and search for development solutions. The Forum has attracted numerous acclaimed local and foreign medical device inventors, medical scientists, entrepreneurs, investors and multinational top management, and boasted good reputation in the industry. Device China 2018 is hosted by Suzhou Industrial Park Biotech Development Co., Ltd. and China Association for Medical Devices Industry together, and planned and organized by Suzhou Innomd Medical Innovation Service Co., Ltd. 500-600 participants are expected in 2019.

Nearly 20 sub-sessions
We are dedicated to organize high quality sub-session in 2019.
Till now, following sub-sessions have been confirmed.

1. FTR4H (Future for Health) digital medical conference
2. 2nd China Medical Beauty Equipment Safety Seminar
3. Ultrasound Medical Industry Development and New Technology Seminar
4. Medical Device Patents and Intellectual Property Protection
5 Medical Materials and Accessories for Devices Seminar
6. Clinical needs of vascular surgical instruments and medico engineering cooperation Seminar
7. Clinical Trial Design and Preclinical Research of Innovative Medical Devices
8. Medical Device Registration Regulations, Registrant System and Commissioned Production
9. 1st China Doctor Innovation and Entrepreneurship Forum
10. IVD Forum?Development & Trends of IVD industry?
11. Workshop-Medical Device Innovation Design
12. Medical Artificial Intelligence technology
13. New Medical Device Market (Application of new materials)
14. IVD? POCT?
15. Medical Device Investment & Acquisition
and many more…

Onsite we will invite more than 300 domestic and overseas speakers, including senior academicians and clinical experts to explore the development trends of the industry through multi-angle analysis of industry innovation pain points!

Shaping the Medical Future by Innovation Technology! Sep. 5th – Sep. 7th, we look forward to meeting you at the Medical Fair China 2019 by the beautiful Jinji Lake!

For more details, please scan the QR code to follow MFC official WeChat account (ID:  medical-fair-china), or visit the official website: www.medicalfair.cn

AO Alliance has announced a collaboration with Johnson & Johnson Corporate Citizenship Trust to improve the quality of and access to fracture care in low- and middle-income countries (LMICs) in West Africa.

The West Africa Trauma Education Program aims to improve health outcomes for patients by building longer-term local capacity for injury and fracture care, and sustainably strengthening health systems, including essential surgery. The three-year collaboration will provide specialized education and training for up to 900 national and regional healthcare workers to deliver safe and timely access to care for the injured.

The first year of the program will support educational activities in Nigeria, Ghana and Ivory Coast.

Dr Claude Martin jr., Managing Director, AO Alliance said: “AO Alliance is committed to reducing avoidable mortality and disability in LMICs by introducing enhanced standards of care for fractures. In many cases, countries with the greatest fracture care needs often have the least resources to address the problem. The West Africa Trauma Education Program, in collaboration with Johnson & Johnson Corporate Citizenship Trust will provide front line healthcare workers with added knowledge and skills to better care for the injured.”

Injuries are among the highest causes of death and disability globally and approximately 90% of these occur in low- and middle-income countries, resulting in an estimated US$180 billion in lost productivity annually.Current inequalities in care and treatment mean that patients with life-threatening but survivable injuries are six times more likely to die in LMICs than in a high-income setting.

Improving access and quality of trauma care has been proven to be effective in saving lives and improving clinical outcomes. It has been estimated that addressing inequalities in trauma care in LMICs could reduce mortality by 15-20 percent, saving more than two million lives each year.

Alissa Hsu Lynch, Vice President and Essential Surgery EMEA Lead, Johnson & Johnson3 said: “Out of a global population of seven billion, five billion currently lack access to safe and affordable anesthesia and surgical care. With approximately a third of the world’s global burden of disease being potentially addressable through surgery, lack of access represents one of the most significant global public health challenges in the world today. Todays’ collaboration announcement with AO Alliance is an important step to addressing this burden by ensuring more people are able to access safe, essential and timely surgical care when they need it and brings Johnson & Johnson closer to our five-year goal of ensuring that 50 million people will have had access to safe, essential, and timely surgical care.”

About AO Alliance
AO Alliance is a developmental non-profit organization dedicated to improving the care of the injured in low- and middle-income countries (LMICs). Our mission is to reduce human suffering, disability and poverty. We envision a world where timely and appropriate fracture care is accessible to everyone. This goal can be achieved by implementing innovative, sustainable and effective programs that enhance fracture care.

About Johnson & Johnson Medical Devices Companies
As the world’s most comprehensive medical devices business, we are building on a century of experience, merging science and technology, to shape the future of health and benefit even more people around the world. With our unparalleled breadth, depth and reach across surgery, orthopaedics, vision and interventional solutions, we’re working to profoundly change the way care is delivered. We are in this for life.

Using mobile technology to break access and awareness barriers in hypertension and diabetes: that is what the new ‘Tiba Yako’ program strives for. The initiative was launched recently in Nairobi, Kenya, by Boehringer Ingelheim, one of the world’s leading pharmaceutical companies and PharmAccess, a non-profit organization that works to improve access to quality healthcare in Africa. Tiba Yako seeks to support care for patients in Nairobi, Kiambu and Vihiga County through screening sessions, clinical care and home-based monitoring as well as digital awareness and adherence advice. The mobile phone is the linking pin in this integrated approach.

Core of the Tiba Yako program is a digital payment platform for inclusive healthcare called M-TIBA. M-TIBA, developed by Pharm Access and partners, enables people to save, send, receive and pay money for medical treatment through a mobile health wallet on their phone. The digital platform allows for a more efficient and transparent way of connecting patients, doctors and payers as it is based on a constant flow of almost real-time data. Within the Tiba Yako program, M-TIBA will now also provide access support for hypertension and diabetes care in selected clinics of the country.

The program allows patients to monitor their blood pressure and blood glucose levels at their convenience at home, digitally sending the results to their doctor for review. Combined with digital awareness and self-management support through an innovative app called Afya Pap, this integrated approach aims to increase symptom recognition and treatment adherence.

The data that is collected in real time through the M-TIBA mobile wallet as well as the home monitoring guides doctors and healthcare providers in their health population management. For Payers, the real time data insights in the costs, efficiency and quality of care means an improved cost-efficiency. This could stimulate insurers to enlarge their addressable market to lower socio-economic levels than their current patient base.

The Tiba Yako program is in line with the ‘In Reach Africa’ initiative of Boehringer Ingelheim, which aims at facilitating quality and access of human and animal healthcare across the African continent. “Our fundamental priority in the region is to develop solutions that enable screening and education. With Tiba Yako, we have a clear strategy in place to improve access to healthcare for those in need’’, said Ayman Eissa, Head of Human Pharmaceuticals across the Sub Saharan Africa at Boehringer Ingelheim.

There is currently an unmet need for efficient and widely accessible care for hypertension and diabetes in Kenya. The prevalence among adults is high, with low levels of awareness, treatment and control. The high mobile penetration rates in Kenya – also amongst the low-income groups – creates massive opportunities for direct service and financing models. Digital technology can be used to increase healthcare access for people who are currently underserved and enables people to self-manage and control their disease from home.

Notably, over 50% of patients with diabetes or hypertension are not aware of their diagnosis. Many have scarce knowledge of non-communicable diseases (NCDs) or are not compliant with treatment. Chronic diseases such as diabetes have serious implications if left uncontrolled, including microvascular damage to blood vessels, and microvascular damage to eyesight, nerves and feet

Boehringer Ingelheim
Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and bio-pharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

Initiative “In Reach Africa”
The ‘In Reach Africa’ initiative by Boehringer Ingelheim aims at facilitating quality and innovative human and animal healthcare access across the African continent. It shares a collective vision of driving accessibility, sustainability and innovation through enhancing health systems in Africa. This is achievable by providing an accessible range of medication and healthcare solutions, increasing awareness of key disease priorities through reach and enriching knowledge and education initiatives. In doing so, this initiative will add more value to the socioeconomic structure by working with and supporting low-income families on multiple fronts.

The program, recently launched in Kenya, is set to expand throughout major African markets including Nigeria, Ghana, Ethiopia, Uganda, Mozambique, Tanzania, Zambia, Zimbabwe and Rwanda.

Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.